Elixiron Immunotherapeutics (Cayman) Limited
Update：2026/02/24
Industries
Main Industry
Biotechnology
Main Product/Service
1. Precision Immunotherapy
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
Founded Year
2025
Unified Business No.
60600720
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2026)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Elixiron Immunotherapeutics focuses on developing precision immunotherapies targeting neuroinflammation, autoimmune diseases, and cancer. Leveraging deep expertise in immunology and drug development, the company has advanced two high-potential lead candidates into clinical trials: EI-1071 (Enrupatinib), for Alzheimer’s disease, ALS, Parkinson’s disease, and idiopathic pulmonary fibrosis, and EI-001 (Indemakitug), for vitiligo, hemophagocytic syndrome, and alopecia areata.
